Table 8.
In vitro ADME profile of the most potent inhibitor, NBCoV63.
| Assay Performed | In Vitro ADMET | Inhibitor |
|---|---|---|
| NBCoV63 | ||
| Solubility (µM) | Phosphate buffer, pH7.4 | 6.25 |
| Caco-2 permeability (mean Papp, ×10−6 cm/s) |
A-to-B | 0.00242 |
| B-to-A | 0.19 | |
| Efflux Ratio | 42.3 | |
| Metabolic stability (human liver microsomes) |
Clint (µL/min/mg protein) | 3.4 |
| Half-life (min) | >180 | |
| Protein binding (human plasma) | % bound | >99.5 |
| Cytochrome P450 inhibition, IC50 (µM) | CYP1A2 (a-Naphthoflavone) | >25 |
| CYP2B6 (Ticlopidine) | >25 | |
| CYP2C8 (Quercetin) | >25 | |
| CYP2C9 (Sulphaphenazole) | >25 | |
| CYP2C19 (Ticlopidine) | >25 | |
| CYP2D6 (Quinidine) | >25 |